A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 1,200 shares of HBIO stock, worth $3,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,200
Previous 4,000 70.0%
Holding current value
$3,335
Previous $16,000 81.25%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.77 - $4.63 $294,680 - $492,553
106,383 Added 560.32%
125,369 $357,000
Q1 2024

May 15, 2024

BUY
$4.02 - $5.39 $76,323 - $102,334
18,986 New
18,986 $80,000
Q3 2023

Nov 14, 2023

SELL
$4.0 - $5.82 $7,504 - $10,918
-1,876 Reduced 49.81%
1,890 $8,000
Q2 2023

Aug 14, 2023

SELL
$4.19 - $6.16 $112,547 - $165,463
-26,861 Reduced 87.7%
3,766 $20,000
Q1 2023

May 15, 2023

SELL
$2.45 - $4.22 $28,045 - $48,306
-11,447 Reduced 27.21%
30,627 $128,000
Q4 2022

Feb 14, 2023

BUY
$2.12 - $2.86 $56,898 - $76,759
26,839 Added 176.17%
42,074 $116,000
Q3 2022

Nov 14, 2022

SELL
$2.33 - $3.92 $311,539 - $524,135
-133,708 Reduced 89.77%
15,235 $39,000
Q2 2022

Aug 15, 2022

BUY
$3.28 - $6.42 $422,591 - $827,146
128,839 Added 640.86%
148,943 $537,000
Q1 2022

May 16, 2022

BUY
$5.16 - $7.14 $38,488 - $53,257
7,459 Added 58.99%
20,104 $125,000
Q3 2021

Nov 15, 2021

SELL
$6.98 - $8.47 $2,708 - $3,286
-388 Reduced 2.98%
12,645 $88,000
Q1 2021

May 17, 2021

BUY
$3.91 - $6.99 $50,959 - $91,100
13,033 New
13,033 $71,000
Q3 2020

Nov 16, 2020

SELL
$2.75 - $4.2 $123,431 - $188,512
-44,884 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$2.12 - $3.14 $29,226 - $43,288
-13,786 Reduced 23.5%
44,884 $139,000
Q2 2019

Aug 14, 2019

SELL
$1.93 - $4.59 $2,244 - $5,338
-1,163 Reduced 1.94%
58,670 $118,000
Q3 2018

Nov 13, 2018

BUY
$5.0 - $6.65 $235,120 - $312,709
47,024 Added 367.12%
59,833 $0
Q1 2018

May 11, 2018

BUY
$3.3 - $5.15 $42,269 - $65,966
12,809 New
12,809 $64,000

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $116M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.